STAT3 and pancreatic neoplasm: Additionally, YY002, another dual-phosphorylation synchronous inhibitor, effectively suppresses pancreatic cancer growth and metastasis in preclinical models, exhibiting superior therapeutic efficacy compared with the clinical-stage STAT3 inhibitor BBI608 [43].